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Abstract The aim of this study was to investigate the
management and prognostic determinants of recurrent pleo-
morphic adenoma (RPA). A retrospective analysis was per-
formed to examine the clinical features, the prevalence of
surgical complications, and new recurrences of RPA. Tumor
recurrence rate was estimated by the Kaplan–Meier method,
and the prognostic value of some of the variables was tested
by univariate analysis using the log rank test. The study
focused on 33 patients, 18 female (54.5%) and 15 male
(45.5%), aged 12–71 years (median 41). A total or extended
total parotidectomy was performed in 16 cases (48.5%), a
superWcial parotidectomy in 10 cases (30.3%), and a local
excision in 7 cases (21.2%). In ten patients (30.3%), a branch
or the trunk of the facial nerve was deliberately sacriWced.
Major complications included one unexpected deWnitive paral-
ysis of the marginal mandibular branch of the facial nerve and
14 cases of Frey syndrome. Follow-up varied from 2 to
25 years (median 10.5 years), and there were 11 new recur-
rences (33.3%) within a period varying from 1 to 16 years
(median 6 years). The estimated tumor recurrence rates were
14.1 § 6.6% at 5 years, 31.4 § 9.4% at 10 years, 43.0 §
10.8% at 15 years, and 57.2 § 14.8% at 20 years. Presence of
a multinodular lesion and the type of intervention performed
were signiWcantly associated with a higher probability of
recurrence. RPAs are prone to new recurrences, especially
when multinodular and treated with a local excision. Surgical
treatment should include facial nerve resection in selected
cases. Follow-up for the patient’s lifetime is warranted.
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Introduction
Pleomorphic adenoma is the most common neoplasm of the
parotid gland. It is a benign tumor composed of epithelial
and myoepithelial cells arranged in various morphological
patterns. Thinning or absence of the pseudocapsule and the
presence of Wngerlike projections of the tumor have been
observed in all histologic subtypes of pleomorphic ade-
noma, in particular the myxoid type [1]. Even though many
hypotheses for recurrences of parotid gland pleomorphic
adenoma have been advanced, including cell biological and
genetic factors [2,  3], obvious or underestimated tumor
spillage, incomplete excision, and violation of the pseudo-
capsule of the tumor are considered the only proven reasons
contributing to recurrent disease [4].
This is why the abandonment of enucleation techniques
in favor of more extended surgical procedures, which
require the tumor to be excised with the surrounding nor-
mal tissue and the facial nerve to be identiWed and pre-
served, have dramatically reduced the recurrence rate of
pleomorphic adenomas of the parotid gland from 20–45%
to less than 4% in the last decades [5–7].
However, pure en bloc excision in parotid benign tumor
disease has been considered impossible by most surgeons
when the pleomorphic adenoma is lying on the facial nerve,
and so partial enucleation is often the only surgical option
in those cases [5,  7], thus explaining the possibility of
recurrence even after proper surgery.
Most of the recent literature on recurrent pleomorphic
adenoma (RPA) of the parotid gland has attempted to analyze
the causes of primary failure and discusses other possible
L. O. Redaelli de Zinis (&) · M. Piccioni · A. R. Antonelli · 
P. Nicolai
Department of Otorhinolaryngology, 
University of Brescia, Piazza Spedali Civili 1, 
25123 Brescia, Italy
e-mail: redaelli@med.unibs.it; lordz@fastwebnet.it448 Eur Arch Otorhinolaryngol (2008) 265:447–452
123
risk factors for recurrence [8–12]; however, there are very
few papers focused on the prognostic factors of RPA and
retreatment policies [13–18].
The present study was undertaken to address these
important issues based on a follow-up period of up to
20 years. Here, we present our Wndings and review some of
the more recent literature.
Materials and methods
A retrospective analysis of the charts of patients treated for
benign parotid neoplasm between 1983 and 2004 was per-
formed to identify those patients operated on for RPA. We
collected information on patient demographics and clinical
history, clinical features of the lesions, diagnostic work-up,
the type of surgery, operative Wndings, facial nerve man-
agement, and adjuvant treatment.
The study analyzed the prevalence of surgical complica-
tions and new recurrences. Statistical analysis was per-
formed using the SPSS statistical package. Tumor
recurrence rate was estimated by the Kaplan–Meier
method: the entry point was the date of surgery for a recur-
rent tumor seen for the Wrst time in our department, and the
end point was the date of a new recurrence or the date of
last consultation for censored observations.
The prognostic value of certain categorical variables
(age, gender, number of previous operations, type of previ-
ous operation, lobe of origin, type of surgery performed for
RPA, maximum diameter, facial nerve resection, presence
of a pseudocapsule at the surgical margins, rupture of the
pseudocapsule, number of neoplastic nodules, postopera-
tive radiotherapy) was tested by univariate analysis using
the log rank test.
Results
Among 524 patients treated for a benign parotid neoplasm
between 1983 and 2004, 33 underwent surgical treatment for
RPA. Eighteen (54.5%) patients were female and 15 (45.5%)
male; their ages ranged from 12 to 71 years (median 41).
None had been previously aVected by a malignant neoplasm
or submitted to radiation treatment. Seven patients were pre-
viously operated on in our department (with a prevalence of
recurrence after Wrst treatment of 1.3%) and 26 patients had
previous surgical treatment(s) performed elsewhere. A sum-
mary of the patient’s previous clinical history is reported in
Table 1. A swelling in the parotid region was the most sig-
niWcant complaint for 87.9% (29/33) of patients when they
came to our attention for the recurrence; pain or facial nerve
paresis was associated with the swelling in two cases. In four
(12.1%) cases, the relapse was recognized by routine postop-
erative follow-up examinations. Other complaints, present
from previous surgeries, were facial nerve paralysis in four
patients and Frey syndrome in one.
Ultrasonography was the most frequently used diagnos-
tic tool (23 patients, 69.7%), followed by Wne needle aspira-
tion biopsy in 21 (63.6%) patients, magnetic resonance
imaging in 14 (42.4%), computed tomography in 3 (9.1%),
and sialography in 2 (6.1%). The diVerent types of diagnos-
tic procedures employed reXect the multi-decade period
analyzed. At present, after ultrasonography, which is rou-
tinely adopted for follow-up, magnetic resonance imaging
is used to delineate the extension of the recurrent lesions.
In 12 (36.4%) patients, the lesion involved the superW-
cial lobe of the parotid gland, in 9 (27.3%) both lobes, and
in 12 (36.4%) only the deep lobe was involved. In 5
(15.2%) patients the lesion also extended to the parapharyn-
geal space. Information on multinodularity of the lesion
could be obtained for 31 patients: multiple lesions were
observed in 24 (77.4%) of them.
Surgical treatment was tailored to the single patient in an
attempt to obtain a margin of healthy tissue (Table 2). Post-
operative complications are listed in Table 3. Nine (27.3%)
patients were submitted to postoperative radiotherapy.
There were no standard criteria for postoperative radiother-
apy, but it was performed when the excision did not guar-
antee suYcient free margins of healthy tissue based on the
judgment of the surgeon.
The patients were followed by yearly ultrasonography.
Follow-up varied from 2 to 25 years (median 10.5 years).
Three patients died from a metachronous malignant neo-
plasm, one of them after a new recurrence. The other
Table 1 Summary of clinical history of patients treated for the Wrst
time at the Department of Otolaryngology of the University of Brescia
for RPA of the parotid gland
Number of patients in parentheses
Previous recurrences
One 63.6% (21)
Two 18.2%  (6)
Three 12.1%  (4)
Four 6.1%  (2)
Median time to recurrence
First recurrence (33)  6 years (range 1–23)
Second recurrence (12)  5 years (range 2–28)
Third recurrence (6)  5.5 years (range 3–19)
Fourth recurrence (2)  8 years (both patients)
Last operation
Subtotal parotidectomy  33.3% (11)
Local excision  33.3% (11)
SuperWcial parotidectomy  21.2% (7)
Not reported  12.1% (4)Eur Arch Otorhinolaryngol (2008) 265:447–452  449
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patients are still alive. Overall, 11 (33.3%) new recurrences
were observed. No patient with a single node had a recur-
rence. Four of the new recurrences had been operated on
again and one had a further recurrence. Seven patients with
small (less than 1 cm) and stable new recurrences are still
on follow-up. The time for new recurrence varied from 1 to
16 years (median 6 years). There were 2 cases of focal
atypical cells but no malignant transformation in the new
recurrences. Distribution of the recurrences in relation to
the diVerent variables under analysis is shown in Table 4.
The estimated tumor recurrence rates were 14.1 § 6.6% at
5 years, 31.4 § 9.4% at 10 years, 43.0 § 10.8% at
15 years, and 57.2 § 14.8% at 20 years (Fig. 1). Among the
variables evaluated with the log-rank test, only the presence
of a multinodular recurrence and the type of intervention
performed were signiWcantly associated with a higher prob-
ability of a new recurrence (Table 5). The high variation in
tumor recurrence rates observed after 20 years of follow-up
(Table 5) is probably related to the low number of patients
with longer follow-up times.
Discussion
It is generally accepted that the standard treatment of pleo-
morphic adenoma of the parotid gland is a formal paroti-
dectomy or at least the removal of the tumor with a
surrounding cuV of normal parotid tissue after identiWca-
tion, dissection and preservation of the facial nerve [7].
Unfortunately, if the tumor is in contact with the facial
nerve, even a total parotidectomy can not guarantee the
presence of a cuV of normal tissue, because the surgeon
must carry on the dissection between the tumor and the
branches of the nerve with the risk of leaving microscopic
disease behind or causing microscopic spillage of the
Table 2 Surgical treatment for RPA of the parotid gland at the
Department of Otolaryngology of the University of Brescia
Number of patients in parentheses
Total or extended total parotidectomy  48.5% (16)
SuperWcial parotidectomy  30.3% (10)
Local excision  21.2% (7)
Partial or total facial nerve resection 30.3% (10)
Table 3 Postoperative complications of patients treated for RPA of
the parotid gland at the Department of Otolaryngology of the Univer-
sity of Brescia
Frey syndrome  43.7% (14/32)
Temporary paresis of a branch 
or of the entire facial nerve
30.4% (7/23)
DeWnitive paralysis of the marginal 
mandibular branch of the facial nerve
4.3% (1/23)
Salivary Wstula 3.0% (1/33)
Keloid 3.0% (1/33)
Table 4 Distribution of the new recurrences after treatment for RPA
of the parotid gland at the Department of Otolaryngology of the Uni-
versity of Brescia (No. = 11; 33.3%)
Variable % P-value
Age ·30 years (3/10) 30.0 1
>30 years (8/23) 34.8
Gender Female (4/18) 22.2 0.1
Male (7/15) 46.7
Number of previous 
operations
1 (7/21) 33.3 1
>1 (4/12) 33.3
Type of previous 
operations
Enucleation (2/11) 18.2 0.2
Parotidectomy (8/18) 44.4
Lobe of origin SuperWcial (5/21) 23.8 0.1
Deep (6/12) 50.0
Intervention performed Parotidectomy (6/26) 23.1 0.02
Other (5/7) 71.4
Maximum diameter ·2 cm (7/16) 43.8 0.3
>2 cm (3/15) 20.0
Facial nerve resection No (7/23) 30.4 0.7
Yes (4/10) 40.0
Involvement of 
surgical margins
No (8/23) 34.8 0.5
Yes (2/8) 25.0
Capsular rupture No (6/23) 26.1 0.2
Yes (4/8) 50.0
Multiple nodules No (0/7) 0 0.04
Yes (10/24) 41.7
Postoperative 
radiotherapy
No (9/24) 37.5 0.3
Yes (2/9) 22.2
Fig. 1 Estimated recurrence rate after treatment for recurrent pleo-
morphic adenoma of the parotid gland at the Department of Otolaryn-
gology of the University of Brescia (Kaplan–Meier method)450 Eur Arch Otorhinolaryngol (2008) 265:447–452
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tumor. This accounts for 1–4% probability of recurrence [5,
7]. These low percentages, together with the increasing
number of institutions that treat parotid neoplasms, have
reduced the number of cases of RPA being referred to a sin-
gle institution; this, in turn, has contributed to a lack of
experience in managing these tumors. Moreover, with the
number of reported patients usually varying from less than
15 to about 50 [6, 8, 9, 11, 12, 14–17, 19–24], and only a
few studies reporting about a hundred patients [10, 13, 18,
25], there has been relatively little discussion of the prog-
nostic factors for RPA [13–18].
Follow-up of parotidectomies is currently performed by
ultrasonography, but most patients do not avail themselves of
regular follow-up and only 12.1% of our patients with an
RPA were diagnosed by routine ultrasonography, while the
majority came to our observation for a swelling in the parotid
region. In 77.4% of our patients, there was a multinodular
lesion (in Stennert et al. [4], 90% were multinodular at patho-
logic examination), reinforcing the pathogenetic hypothesis
of incomplete excision, violation of the pseudocapsule of the
tumor, or obvious or underestimated tumor spillage during
the Wrst surgery due to the impossibility of obtaining healthy
free margins when the lesion is adjacent to the facial nerve.
Delineation of the extension of the RPA is better
depicted by MRI, which better demonstrates the multinodu-
lar nature of the disease [24] and potential deep-lobe or
parapharyngeal extension. Many patients that we treated
came from other institutions without clear documentation
of their previous treatment(s); in such cases, MRI can also
help in determining the amount of parotid gland still pres-
ent after any previous surgery. The signal and enhancement
characteristics of RPA of the parotid gland are nonspeciWc
[26]. The lesions are usually round; they are of low inten-
sity on T1-weighted images and of high intensity on T2-
weighted MR images. With contrast administration, the
lesions show mild enhancement [26]. However, MRI can
also be inadequate for identifying all nodules, and fre-
quently the surgeon’s microscope or the pathologist’s
microscope reveals many more nodules than suspected
from clinical assessment [4].
Management options for RPA include observation only,
localized resection, resection with facial nerve dissection,
Table 5 Estimated tumor recurrence rates after treatment for RPA of the parotid gland at the Department of Otolaryngology of the University of
Brescia (log-rank test)
Variable Estimated tumor recurrence rates (%) P-value
5-year 10-year 15-year 20-year
Age ·30 years (10) 12.5 § 11.7 41.7 § 18.6 – – 0.8
> 30 years (23) 14.7 § 7.9 26.9 § 10.5 42.4 § 12.8 56.8 § 15.7
Gender Female (18) 13.4 § 9.0 30.7 § 13.1 30.7 § 13.1 30.7 § 13.1 0.4
Male (15) 14.3 § 9.4 30.7 § 13.0 56.7 § 15.1 71.1 § 16.3
Number of previous operations 1 (21) 11.8 § 7.9 25.4 § 11.1 45.6 § 14.7 63.7 § 17.8 0.9
>1 (12) 18.5 § 11.9 41.8 § 16.3 41.8 § 16.3 41.8 § 16.3
Type of last previous operation Enucleation (11) 9.1 § 8.7 24.2 § 15.6 24.2 § 15.6 24.2 § 15.6 0.2
Parotidectomy (18) 20.0 § 10.3 45.1 § 14.0 58.9 § 15.9 100
Lobe of origin SuperWcial (21) 0 13.8 § 9.1 32.1 § 13.6 54.8 § 20.6 0.07
Deep (12) 35.8 § 14.4 59.9 § 16.4 59.9 § 16.4 59.9 § 16.4
Intervention performed Parotidectomy (26) 5.3 § 5.1 16.4 § 8.7 30.5 § 11.7 47.9 § 17.4 0.001
Other (7) 42.9 § 18.7 – – –
Maximum diameter ·2 cm (16) 19.6 § 10.2 26.9 § 11.6 44.3 § 14.0 72.2 § 20.9 0.4
>2 cm (15) 10.0 § 9.5 32.5 § 15.5 32.5 § 15.5 32.5 § 15.5
Facial nerve resection No (23) 9.4 § 6.3 27.2 § 10.6 35.3 § 12.1 51.4 § 16.7 0.4
Yes (10) 25.0 § 15.3 40.0 § 18.2 – –
Involvement of surgical margins No (23) 14.0 § 7.5 24.7 § 9.7 37.9 § 11.7 53.4 § 16.0 0.3
Yes (8) 25.0 § 21.7 62.5 § 28.6 – –
Capsular rupture No (23) 16.4 § 8.8 38.7 § 12.8 38.7 § 12.8 38.7 § 12.8 0.8
Yes (8) 12.5 § 11.7 12.5 § 11.7 40.0 § 18.2 100
Multiple nodules No (7) 0 0 0 0 0.02
Yes (24) 19.6 § 8.9 36.8 § 11.2 53.2 § 13.4 100
Postoperative radiotherapy No (24) 14.2 § 7.7 34.3 § 11.8 48.9 § 12.9 65.9 § 16.4 0.3
Yes (9) 12.5 § 11.6 25.0 § 15.3 25.0 § 15.3 25.0 § 15.3Eur Arch Otorhinolaryngol (2008) 265:447–452  451
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wide-Weld resection with facial nerve sacriWce, and radio-
therapy [2, 4, 24]. Only observation has been suggested for
the elderly or medically inWrm patient [2, 4, 24]. When sur-
gical excision is considered, it should be tailored to the
individual patient [19, 23]. In general, it is recommended to
resect the scars of any previous surgery. Localized resec-
tion of the tumor has been employed after multiple recur-
rences or after previous total parotidectomy when it is the
only option to preserve the facial nerve [10, 14]. SuperWcial
or total parotidectomy, depending on the location of the
recurrence, has been suggested when the previous operation
was a simple local excision [6, 8–15, 17, 18, 20, 23–25].
Radical and extended parotidectomies have been consid-
ered for patients with inWltration of branches or the main
trunk of the facial nerve, and in cases of multinodular
recurrences [9, 11–13, 15, 18, 23–25]. In particular, facial
nerve resection has been suggested for patients with a his-
tory of multiple recurrences or failed radiotherapy [24]. In
30.3% of our patients, the resection of at least a branch of
the facial nerve was performed (Table 2). Facial nerve dis-
section and preservation were performed in all cases with
still healthy parotid tissue between the nerve and the tumor,
and in the case of facial nerve encasement when a patient
refused facial nerve resection. The observation of many
cases with unexpected multinodularity persuaded Stennert
et al. [4] to routinely perform a total parotidectomy for all
RPAs. However, such an aggressive policy of treatment
does not prevent leaving microscopic residuals; indeed, a
recent study by the same group reported a 52% probability
of new recurrences [18].
The role of radiotherapy remains questionable [9, 13, 16,
17, 24, 27]. Some authors suggest that radiotherapy should
be reserved only for malignant tumors since it carries, espe-
cially in young people, a risk of malignant transformation
that increases over time [17]. Nonetheless, its use is not
infrequent [6, 9, 13–16, 19, 20, 27]. Jackson et al. [9] used
postoperative radiotherapy in patients in whom histology
showed that resection margins of the specimen were not
free of tumor or in those with intraoperative spillage of
tumor. Renehan et al. [13] recommended postoperative
radiotherapy in multinodular recurrences. Douglas et al.
[16] reported their experience of fast neutron radiotherapy
and recommended radiotherapy for selected cases: when
complete extirpation is not possible, when sacriWce of the
facial nerve is necessary, or after multiple recurrences. Glas
et al. [17] suggested postoperative radiotherapy for diYcult
cases in which further surgical treatment of recurrent dis-
ease is not recommended for technical reasons. Kamida
et al. [27] suggested the use of stereotactic radiosurgery for
diYcult selected cases, such as the patient they treated for
skull base invasion with no regrowth after 5 years. Our
experience, including only nine patients, is too limited to
draw any conclusion about indications for radiation therapy.
Complications of treatment of RPA are similar to those
for primary surgery for parotid pleomorphic adenoma. The
main diVerence is the higher risk of facial nerve damage in
the former, with unexpected permanent facial nerve paraly-
sis in more than 30% of cases [24].
Even though we did not have cases of malignant trans-
formation, a high incidence is expected, especially after
multiple recurrences, reaching up to 15% in the experience
of Mercante et al. [22].
The main purpose of our study was to analyze risk factors
for new recurrence after treatment for RPA. The percentage
of new recurrences varies from 10 to 58% [8, 10, 12–15, 17–
20, 23–25]. In two surveys of the literature with a 10-year
follow-up, the prevalence of a new recurrence was 43 and
45%, respectively [12, 25]. Wittekindt et al. [18] reported a
recurrence rate increasing from 42% at 5 years to 75% at
15 years. We observed a prevalence of 33.3% with an esti-
mation of recurrence rate increasing from 14.1 § 6.6% at
5 years to 31.4 § 9.4% at 10 years, 43.0 § 10.8% at
15 years, and 57.2 § 14.8% at 20 years (Fig. 1).
Among the variables tested with the log-rank test against
the estimated new recurrence rate (Table 5), just two were
signiWcantly associated with the likelihood of developing a
new recurrence: local excision of the RPA instead of a for-
mal parotidectomy and the presence of multinodular dis-
ease. To date, no new recurrences have been observed for
uninodular recurrences. There was a trend toward increased
risk of a new recurrence for deep-lobe localization,
although it was not statistically signiWcant.
Few papers have analyzed prognostic factors for RPA
[13–18]. Renehan et al. [13] studied 114 patients with Wrst-
recurrence RPA and reported signiWcantly better, new recur-
rence-free survival for patients treated with postoperative
radiotherapy when the RPA was multinodular. Age, gender,
time to Wrst recurrence, and the type of prior treatment were
all not signiWcant predisposing factors for a new recurrence
[13]. Yugueros et al. [14] followed 39 patients treated for
RPA at their institution: they found no signiWcant diVerence
in development of another recurrence in relation to gender,
time after the previous treatment, size of the tumor, type of
resection, and postoperative radiotherapy. Carew et al. [15]
analyzed 31 patients treated for RPA and concluded that the
extent of the Wrst parotid operation was the only factor with a
statistically signiWcant impact on tumor control after resec-
tion of the recurrence. Local control was achieved in all
patients whose initial procedures involved local excision.
SuperWcial lobe location and postoperative radiotherapy
showed better results but were not signiWcant [15]. Fast neu-
tron radiotherapy of 16 patients with residuals of RPA
stopped progression of the tumor in patients without gross
residuals, without multifocal disease and with an interval
from diagnosis of less than 25 years; however, the results
were not statistically signiWcant [16]. Glas et al. [17] ana-452 Eur Arch Otorhinolaryngol (2008) 265:447–452
123
lyzed 52 patients with RPA, treated after one or more recur-
rences: no signiWcant inXuence was seen in the recurrence
rate with respect to gender, age at initial treatment, time of
Wrst recurrence, and intraoperative tumor spillage. Wittekindt
et al. [18], in a group of 108 patients, observed a signiWcantly
higher rate of new recurrences in female patients, in younger
patients, and in patients treated with a simple enucleation.
Conclusion
The management of RPA is a major challenge for the clini-
cian. RPAs, particularly multinodular tumors, are prone to
new recurrences especially when treatment of the initial
tumor is performed according to currently accepted stan-
dards. MRI is considered to be the best tool to delineate the
extension of the lesion, although it can miss microscopic
nodules. Options for management include pure observation,
not only for the elderly or inWrm, but also in cases of small
lesions until they begin to grow. When surgery is elected, it
should be tailored to the single patient, because even if on
one side a limited local excision is considered acceptable, on
the other side a total or extended parotidectomy may be
inadequate to control an RPA adjacent to the nerve. In these
cases, facial nerve resection and reconstruction must also be
considered and discussed with the patient in the preoperative
counseling. Postoperative radiotherapy is an option, particu-
larly for older patients for whom the risk of inducing other
malignancies is considered to be low. Follow-up for patients
treated for RPA should be done with regular ultrasonogra-
phy for the lifetime of the patient and with magnetic reso-
nance in selected cases with deep lobe or parapharyngeal
involvement. All patients should be informed about the pos-
sibility of the need for multiple treatment procedures.
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